Skip to content
Nonprofiteer
← JAEB CENTER FOR HEALTH RESEARCH INC

Form 990 for tax year 2023

Filed by JAEB CENTER FOR HEALTH RESEARCH INC.

Totals

Total revenue
$53,220,979
Total expenses
$44,888,416
Contributions and grants received
$35,083,784
Grants paid
$911,714
Program service revenue
$17,927,381
Investment income
$209,814
Other revenue
$0
Total assets, end of year
$23,767,716
Total liabilities, end of year
$19,487,316
Net assets or fund balances, end of year
$4,280,400
Program services expenses (Part IX)
$37,585,083
Management and general expenses
$7,303,333
Fundraising expenses
$0
Program service expenses (Part III)
$37,585,083

Program services were 83.7% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1d · Related organizations

    $6,177,957

  • 1e · Government grants (contributions)

    $18,644,335

  • 1f · All other contributions, gifts and grants

    $10,261,492

  • 2a · Program service revenue: INDUSTRY PROGRAM SERVICE EXCHANGE

    total $17,927,381 · related or exempt $17,927,381

  • 3 · Investment income

    total $206,410 · excluded $206,410

  • 7a · Gross sales of assets other than inventory

    securities $2,283,000

  • 7b · Less cost or other basis and sales expenses

    securities $2,279,596

  • 7c · Gain or loss

    securities $3,404

  • 7d · Net gain or loss

    total $3,404 · excluded $3,404

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $911,714 · program services $911,714

  • 5 · Compensation of officers, directors and key employees

    total $1,401,020 · program services $412,463 · management and general $988,557

  • 7 · Other salaries and wages

    total $12,636,855 · program services $9,409,039 · management and general $3,227,816

  • 8 · Pension plan contributions

    total $1,950,641 · program services $1,395,712 · management and general $554,929

  • 9 · Other employee benefits

    total $1,341,277 · program services $979,772 · management and general $361,505

  • 10 · Payroll taxes

    total $1,099,269 · program services $773,683 · management and general $325,586

  • 11b · Fees: legal

    total $25,187 · management and general $25,187

  • 11c · Fees: accounting

    total $125,887 · management and general $125,887

  • 11f · Fees: investment management

    total $3,813 · management and general $3,813

  • 11g · Fees: other

    total $1,040,420 · program services $933,222 · management and general $107,198

  • 12 · Advertising and promotion

    total $1,202 · management and general $1,202

  • 13 · Office expenses

    total $32,360 · management and general $32,360

  • 14 · Information technology

    total $651,967 · program services $1,152 · management and general $650,815

  • 16 · Occupancy

    total $507,952 · management and general $507,952

  • 17 · Travel

    total $1,000,683 · program services $964,533 · management and general $36,150

  • 22 · Depreciation, depletion and amortization

    total $109,083 · management and general $109,083

  • 23 · Insurance

    total $135,013 · management and general $135,013

  • 24a · Other expenses: SUBCONTRACTOR PAYMENTS

    total $18,433,305 · program services $18,433,305

  • 24b · Other expenses: RESEARCH EXPENSES

    total $3,321,200 · program services $3,321,200

  • 24c · Other expenses: TRAINING

    total $53,457 · program services $1,350 · management and general $52,107

  • 24d · Other expenses: DUES & SUBSCRIPTIONS

    total $37,697 · management and general $37,697

  • 24e · All other expenses

    total $68,414 · program services $47,938 · management and general $20,476

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $4,590,445 · end of year $9,063,779

  • 2 · Savings and temporary cash investments

    beginning of year $0 · end of year $2,633,881

  • 3 · Pledges and grants receivable

    beginning of year $5,073,199 · end of year $7,699,495

  • 4 · Accounts receivable

    beginning of year $0 · end of year $12,138

  • 9 · Prepaid expenses and deferred charges

    beginning of year $183,416 · end of year $464,581

  • 10a · Land, buildings and equipment: cost or other basis

    $1,280,054

  • 10b · Land, buildings and equipment: accumulated depreciation

    $1,041,604

  • 10c · Land, buildings and equipment, net

    beginning of year $149,921 · end of year $238,450

  • 11 · Investments: publicly traded securities

    beginning of year $0 · end of year $2,574,929

  • 15 · Other assets

    beginning of year $452,137 · end of year $1,080,463

  • 17 · Accounts payable and accrued expenses

    beginning of year $1,406,415 · end of year $4,597,583

  • 19 · Deferred revenue

    beginning of year $12,707,254 · end of year $13,768,197

  • 25 · Other liabilities

    beginning of year $425,060 · end of year $1,121,536

  • 27 · Net assets without donor restrictions

    beginning of year -$4,089,611 · end of year $4,280,400

Mission and programs · 2023

Mission

OUR MISSION IS TO EXPAND SCIENTIFIC KNOWLEDGE AND IMPROVE PUBLIC HEALTH BY DESIGNING AND CONDUCTING WORLD-CLASS CLINICAL TRIALS AND EPIDEMIOLOGIC RESEARCH.

Activities or mission (Part I)

DESIGN AND CONDUCT WORLD-CLASS CLINICAL TRIALS AND EPIDEMIOLOGIC RESEARCH.

  • SEE SCHEDULE O DURING 2023, JCHR WAS ENGAGED IN 53 CLINICAL STUDIES. THESE STUDIES RESULTED IN 42 SCIENTIFIC PUBLICATIONS AND 59 PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS.IN 2023, JCHR RECEIVED GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (8), HELMSLEY CHARITABLE TRUST (8), JDRF (6), FOUNDATION FIGHTING BLINDNESS (5), CYSTIC FIBROSIS FOUNDATION (4), AND FOOD AND DRUG ADMINISTRATION (1). COLLABORATIONS WITH INDUSTRY CONTINUE TO FORM AN INTEGRAL PART OF OUR BUSINESS. JCHR WAS ENGAGED IN STRATEGIC COLLABORATIONS WITH 10 INDUSTRY PARTNERS IN 2023. THESE COLLABORATIONS SPANNED 15 STUDIES. SEVERAL STUDIES ARE FUNDED BY MULTIPLE SOURCES. FOR EXAMPLE, ONE CLINICAL TRIAL EVALUATING FENOFIBRATE FOR DIABETIC RETINOPATHY IS A LARGE COLLABORATION WITH FUNDS PROVIDED BY THE NATIONAL INSTITUTES OF HEALTH (NATIONAL EYE INSTITUTE AND NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASE), JDRF, HELMSLEY CHARITABLE TRUST, AND ROCHE. JCHR ALSO SELF-FUNDED TWO STUDIES AND NUMEROUS STATISTICAL ANALYSIS PROJECTS USING DATASETS FROM PREVIOUSLY COMPLETED STUDIES. AMONG 2,894 ENTITIES RECEIVING NIH FUNDING IN 2023, JCHR RANKS IN THE TOP 8 PERCENT. OUT OF 66,149 NIH GRANTS PROVIDED IN 2023, JCHR HAD THE 136TH- (TOP 0.2 PERCENT) AND 210TH- (TOP 0.3 PERCENT) LARGEST GRANTS (SOURCE: BLUE RIDGE INSTITUTE FOR MEDICAL RESEARCH, 2023).IN 2023, THE JCHR COORDINATED RANDOMIZED TRIAL OF A BIONIC PANCREAS IN INDIVIDUALS WITH TYPE 1 DIABETES LEAD TO FDA 510(K) CLEARANCE FOR THE BETA BIONICS ILET BIONIC PANCREAS. IN ADDITION, RESULTS FROM THE DEXCOM SPONSORED MOBILE STUDY (COORDINATED BY JCHR) SERVED AS THE PRIMARY PIECE OF CLINICAL EVIDENCE THAT LED TO MEDICARE COVERAGE EXPANSION FOR CONTINUOUS GLUCOSE MONITORS, PROVIDING COVERAGE TO PEOPLE WITH DIABETES USING INSULIN, IRRESPECTIVE OF DIABETES TYPE.RESULTS FROM JCHR-AUTHORED MANUSCRIPTS INCLUDE THE FOLLOWING TWO THAT WERE PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE AND THREE PUBLISHED IN JAMA:A STUDY INVOLVING PREGNANT WOMEN WITH TYPE 1 DIABETES COMPARED THE EFFECTIVENESS OF STANDARD INSULIN THERAPY TO HYBRID CLOSED-LOOP THERAPY, WHICH USES CONTINUOUS GLUCOSE MONITORING. THE RESULTS SHOWED THAT THE CLOSED-LOOP THERAPY GROUP HAD SIGNIFICANTLY BETTER GLYCEMIC CONTROL DURING PREGNANCY COMPARED WITH THE STANDARD-CARE GROUP, WITH FEWER INSTANCES OF HYPERGLYCEMIA AND IMPROVED OVERNIGHT GLUCOSE LEVELS, INDICATING THE POTENTIAL BENEFITS OF THIS APPROACH FOR MANAGING TYPE 1 DIABETES DURING PREGNANCY.IN A 13-WEEK TRIAL INVOLVING YOUNG CHILDREN (AGED 2 TO UNDER 6 YEARS) WITH TYPE 1 DIABETES, A CLOSED-LOOP SYSTEM OF INSULIN DELIVERY WAS COMPARED WITH STANDARD CARE USING EITHER AN INSULIN PUMP OR MULTIPLE DAILY INJECTIONS WITH A CONTINUOUS GLUCOSE MONITOR. RESULTS SHOWED THAT CHILDREN USING THE CLOSED-LOOP SYSTEM SPENT SIGNIFICANTLY MORE TIME WITHIN THE TARGET RANGE COMPARED WITH THOSE IN THE STANDARD-CARE GROUP.IN A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL INVOLVING CHILDREN AND ADOLESCENTS NEWLY DIAGNOSED WITH TYPE 1 DIABETES, THE EFFECTS OF VERAPAMIL, A CALCIUM CHANNEL BLOCKER, WERE INVESTIGATED ON PANCREATIC BETA CELL FUNCTION. PARTICIPANTS RECEIVING VERAPAMIL DEMONSTRATED A 30 PERCENT HIGHER C-PEPTIDE LEVEL AT 52 WEEKS COMPARED WITH THOSE ON A PLACEBO, INDICATING PARTIAL PRESERVATION OF PANCREATIC BETA CELL FUNCTION. FURTHER STUDIES ARE NEEDED TO ASSESS THE LONG-TERM DURABILITY OF C-PEPTIDE IMPROVEMENT AND DETERMINE THE OPTIMAL DURATION OF THERAPY. IN A RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL INVOLVING YOUTH WITH NEWLY DIAGNOSED TYPE 1 DIABETES, INTENSIVE DIABETES MANAGEMENT, INCLUDING THE USE OF AN AUTOMATED INSULIN DELIVERY SYSTEM, WAS COMPARED TO STANDARD CARE. THE STUDY AIMED TO DETERMINE IF ACHIEVING NEAR NORMALIZATION OF GLUCOSE LEVELS IMMEDIATELY AFTER DIAGNOSIS COULD PRESERVE PANCREATIC BETA CELL FUNCTION. DESPITE ACHIEVING EXCELLENT GLUCOSE CONTROL, THE INTENSIVE MANAGEMENT GROUP DID NOT SHOW A SIGNIFICANT DIFFERENCE IN PANCREATIC C-PEPTIDE SECRETION DECLINE AT 52 WEEKS COMPARED TO THE STANDARD CARE GROUP, SUGGESTING THAT THIS APPROACH DID NOT IMPACT THE PRESERVATION OF BETA CELL FUNCTION IN THE STUDIED POPULATION.A STUDY COMPARING INTRAVITREAL AFLIBERCEPT TREATMENT TO A SHAM PROCEDURE IN INDIVIDUALS WITH MODERATE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY (NPDR) WITHOUT CENTER-INVOLVED DIABETIC MACULAR EDEMA (CI-DME) REVEALED THAT OVER FOUR YEARS, AFLIBERCEPT SIGNIFICANTLY REDUCED THE LIKELIHOOD OF DEVELOPING VISION-THREATENING COMPLICATIONS COMPARED TO THE SHAM PROCEDURE. HOWEVER, DESPITE ANATOMICAL IMPROVEMENT, THERE WAS NO SIGNIFICANT DIFFERENCE IN VISUAL ACUITY BETWEEN THE TWO GROUPS. THE STUDY SUGGESTS THAT USING AFLIBERCEPT PREVENTIVELY IN PATIENTS WITH NPDR WITHOUT CI-DME MAY NOT BE GENERALLY NECESSARY BASED ON THE OBSERVED OUTCOMES.JCHR'S INVOLVEMENT IN DIABETES STUDIES CONTINUES TO EXPAND AS IT SOLIDIFIED ITS REPUTATION AS THE PREMIERE COORDINATING CENTER WORLDWIDE FOR DIABETES DEVICE STUDIES.

    Expenses $37,585,083 · Grants $911,714 · Revenue $17,927,381

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Roy Beck

    MEDICAL DIRECTOR (PRESIDENT THRU 09/23)

    Total calculated
    $574,043
    From this org
    $486,749
    From related orgs
    $0
    Other
    $87,294
    Hours/week
    40 + 1 related

    Schedule J breakdown matched by us

    Base
    $486,749
    Bonus
    $0
    Other
    $0
    Deferred
    $22,838
    Nontaxable benefits
    $64,456
    Filer's total
    $574,043
  • Dana Ball

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1 + 1 related
  • Neil Bressler

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1 + 1 related
  • Anne Lindblad

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1 + 1 related
  • Shan Shikarpuri

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1 + 1 related
  • Erica Vogt

    CHIEF FINANCIAL OFFICER

    Total calculated
    $238,794
    From this org
    $221,629
    From related orgs
    $0
    Other
    $17,165
    Hours/week
    40 + 1 related

    Schedule J breakdown matched by us

    Base
    $221,629
    Bonus
    $0
    Other
    $0
    Deferred
    $9,500
    Nontaxable benefits
    $7,665
    Filer's total
    $238,794
  • Adam Glassman

    PRESIDENT (EXECTIVE DIRECTOR THRU 09/23)

    Total calculated
    $377,040
    From this org
    $332,525
    From related orgs
    $0
    Other
    $44,515
    Hours/week
    40 + 1 related

    Schedule J breakdown matched by us

    Base
    $332,525
    Bonus
    $0
    Other
    $0
    Deferred
    $15,000
    Nontaxable benefits
    $29,515
    Filer's total
    $377,040
  • Jeannie Perkins

    CHIEF RESEARCH COMPLIANCE OFFICER

    Total calculated
    $211,143
    From this org
    $190,500
    From related orgs
    $0
    Other
    $20,643
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $190,500
    Bonus
    $0
    Other
    $0
    Deferred
    $8,400
    Nontaxable benefits
    $12,243
    Filer's total
    $211,143
  • Craig Kollman

    DIRECTOR OF BIOSTATISTICS

    Total calculated
    $282,778
    From this org
    $243,094
    From related orgs
    $0
    Other
    $39,684
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $243,094
    Bonus
    $0
    Other
    $0
    Deferred
    $11,250
    Nontaxable benefits
    $28,434
    Filer's total
    $282,778
  • Allison Ayala

    BIOSTATISTICIAN IV

    Total calculated
    $204,860
    From this org
    $185,529
    From related orgs
    $0
    Other
    $19,331
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $185,529
    Bonus
    $0
    Other
    $0
    Deferred
    $8,150
    Nontaxable benefits
    $11,181
    Filer's total
    $204,860
  • B Michele Melia

    BIOSTATISTICIAN V

    Total calculated
    $244,134
    From this org
    $224,250
    From related orgs
    $0
    Other
    $19,884
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $224,250
    Bonus
    $0
    Other
    $0
    Deferred
    $9,713
    Nontaxable benefits
    $10,171
    Filer's total
    $244,134
  • Peter Calhoun

    BIOSTATISTICIAN IV

    Total calculated
    $222,507
    From this org
    $202,727
    From related orgs
    $0
    Other
    $19,780
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $202,727
    Bonus
    $0
    Other
    $0
    Deferred
    $9,250
    Nontaxable benefits
    $10,530
    Filer's total
    $222,507
  • Raymond Kraker

    EPIDEMIOLOGIST IV

    Total calculated
    $208,630
    From this org
    $168,949
    From related orgs
    $0
    Other
    $39,681
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $168,949
    Bonus
    $0
    Other
    $0
    Deferred
    $8,300
    Nontaxable benefits
    $31,381
    Filer's total
    $208,630

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 3
THE BOARD OF DIRECTORS SHALL ANNUALLY REVIEW AND APPROVE THE COMPENSATION OF THE CORPORATE OFFICERS, ANY KEY EMPLOYEES (AS DEFINED BY THE IRS), AND THE NEXT FIVE HIGHEST COMPENSATED EMPLOYEES AS LISTED ON THE ORGANIZATION'S PRIOR YEAR FORM 990. IT IS THE BOARD'S INTENTION THAT THIS POLICY AND ITS ASSOCIATED PROCEDURES WILL MEET THE REBUTTABLE PRESUMPTION TEST UNDER IRC 4958 AND TREASURY REGULATION 53.4958-6. THE PURPOSE OF THE ANNUAL REVIEW IS TO ENSURE THAT THE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE BOARD WILL KEEP ROBUST MINUTES OF ITS DELIBERATIONS AND DECISIONS, THE PRESIDENT'S REPORTS, THE CORPORATE TREASURER'S REPORTS, AND ANY OTHER SUPPORTING DOCUMENTATION THAT IT RELIES ON FOR ITS COMPENSATION DECISIONS. ALL THESE DOCUMENTS WILL BE DELIVERED TO THE CORPORATE SECRETARY PROMPTLY AFTER THE BOARD MEETING FOR ENTRY INTO THE CORPORATE BOOKS AND RECORDS.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

Activities outside the United States

From Schedule F of this return, as filed.

Offices (line 3c)
0
Employees, agents and contractors (line 3c)
8
Expenditures and investments (line 3c)
$213,759

At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.

Activities by region (Part I)

Region Offices Employees Activity Specific services Expenditures
NORTH AMERICA 0 3 PROGRAM SERVICES CLINICAL RESEARCH SITES CONTRACTED TO ENROLL PATIENTS AND CONDUCT RESEARCH ACTIVITIES $46,656
EUROPE (INCLUDING ICELAND & GREENLAND) 0 4 PROGRAM SERVICES CLINICAL RESEARCH SITES CONTRACTED TO ENROLL PATIENTS AND CONDUCT RESEARCH ACTIVITIES $153,123
MIDDLE EAST AND NORTH AFRICA 0 1 PROGRAM SERVICES CLINICAL RESEARCH SITES CONTRACTED TO ENROLL PATIENTS AND CONDUCT RESEARCH ACTIVITIES $13,980
Transferred property to a foreign corporation during the year (line 1)
No
Had an interest in a foreign trust (line 2)
No
Owned an interest in a foreign corporation (line 3)
No
Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
No
Owned an interest in a foreign partnership (line 5)
No
Had operations in or related to a boycotting country (line 6)
No

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

Provenance

Return type
form_990
Tax year
2023
Filed
2 April 2024
IRS schema version
2023v5.0
Source object
202430969349301203

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.